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Abstract
Background: The red cell distribution width–platelet ratio (RPR), a novel inflammatory marker 
is currently used to predict inflammation in chronic diseases. It may be associated with adverse 
outcomes among artery disease but its prognostic value in ST-segment elevation myocardial in-
farction (STEMI) treated with primary percutaneous coronary intervention (PCI) has not been 
fully investigated. There is no data regarding the association between RPR and in-hospital major 
adverse cardiovascular events (MACEs). This study evaluated the relations between pre-procedural 
RPR and the in-hospital and long-term outcomes in STEMI patients undergoing primary PCI.
Methods: This study included 580 STEMI patients (77% men, mean age: 59 ± 12 years). 
The patients were divided into two groups according to thrombolysis in myocardial infarction 
(TIMI) flow grades after primary PCI. No-reflow was defined as a post-PCI TIMI flow grade 
of 0, 1 or 2 (group 1). Angiographic success was defined as TIMI flow grade 3 (group 2).
Results: Whole blood cell count, neutrophil and lymphocyte percentages, red cell distribution 
width, platecrit, neutrophil–lymphocyte ratio (NLR) and RPR values were higher among pa-
tients with no-reflow. On multivariate analysis, pain to balloon time, multivessel disease, TIMI 
thrombus grade, tirofiban, aspirin, previous coronary artery disease, NLR, platecrit and RPR 
remained independent predictors of no-reflow after primary PCI. Patients in no-reflow group 
tended to be higher percent in-hospital MACE, including nonfatal myocardial infarction and 
cardiovascular mortality compared to the reflow patients.
Conclusions: Admission NLR, platecrit and RPR are independent correlates of no-reflow and 
in-hospital MACEs among patients with STEMI undergoing primary PCI. (Cardiol J 2016; 
23, 1: 84–92)
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Inflammation plays a role in the initiation 
and progression of the atherosclerotic process 
[1]. Early reperfusion with primary percutaneous 
coronary intervention (PCI) significantly improves 
the survival of patients with ST-segment elevation 
myocardial infarction (STEMI). Coronary artery 
diseases (CAD), and particularly STEMI, are the 
leading causes of morbidity and mortality. The “no-
-reflow” phenomenon manifests as an acute reduc-
tion in coronary blood flow in the absence of major 
epicardial coronary vessel obstruction, flow-limit-
ing dissection, vessel spasm or thrombosis [2]. No- 
-reflow is an important complication among patients 
with acute STEMI undergoing primary PCI [3]. 
The no-reflow phenomenon has been investigated 
extensively in the basic science laboratory and has 
entered the clinical arena. The pathophysiological 
mechanisms of no-reflow phenomenon have not 
been completely understood and its etiology ap-
pears to be multifactorial. Experimental models 
for no-reflow phenomenon include neutrophil 
accumulation, reactive oxygen species, and the 
coagulation cascade via endothelial dysfunction 
and microvascular constriction [4]. Moreover, the 
term “no-reflow” should be reserved for patients 
with thrombolysis in myocardial infarction (TIMI) 
grade 0 or 1 flow in the absence of other etiologies 
with “slow flow” referring to TIMI grade 2 flow [5]. 
No-reflow following primary PCI is independently 
associated with increased in-hospital mortality, 
malignant arrhythmias and cardiac failure. Persis-
tent no-reflow may also result in post-procedural 
myocardial infarction (MI) or extension of MI, and 
is associated with a poor long-term prognosis [6].
The complete blood count (CBC) is one of 
the most frequently ordered laboratory tests in 
clinical practice. Various studies have evaluated 
the performance of these hematological CBC pa-
rameters to predict disease severity and mortality 
risk. Automated cell counters are routinely avail-
able in many clinical laboratories and can be used 
to determine red cell distrubiton width (RDW), 
platecrit, platelet count and and some ratios like 
neutrophil–lymphocyte ratio (NLR), RDW-platelet 
ratio (RPR). Platecrit and NLR have been known 
as independent predictors of impaired angiographic 
reperfusion and long-term mortality among STEMI 
patients treated with primary PCI [7, 8]. The RPR 
a novel routinely available, inexpensive and easily 
calculated index, can predict inflammation [9]. The 
RPR has recently been investigated as a new pre-
dictor for major adverse cardiovascular outcomes. 
There is no data, however, regarding the prognostic 
value of RPR in the prediction of postprocedural 
no-reflow and in-hospital major adverse cardio-
vascular events (MACEs) among STEMI patients 
undergoing primary PCI. Accordingly, we assessed 
the relationship between RPR and the no-reflow 
phenomenon in patients who underwent primary 
PCI for acute STEMI.
Methods
Patients
We examined data of consecutive 855 STEMI 
patients treated by primary PCI in two tertiary 
referral center from 2014 to 2015. Among them, 
275 patients were excluded from the study because 
of not undergoing primary PCI (n = 75), missing 
data (n = 175) or ineligibility to study (n = 25). 
A total of 580 STEMI patients (77% men, mean 
age: 59 ± 12 years) admitted within 12 h from 
symptom onset were included into the study. All 
the patients underwent primary PCI. The diagnosis 
of acute STEMI was established by using The joint 
European Society of Cardiology, American College 
of Cardiology Foundation, the American Heart As-
sociation, and the World Heart Federation (ESC/ 
/ACCF/AHA/WHF) committee for the definition of 
MI established specific electrocardiography (ECG) 
criteria for the diagnosis of STEMI [10]. Coronary 
blood flow was analyzed according to TIMI flow 
grade [11]. Coronary no-reflow was defined as TIMI 
flow grade < 3 without clear evidence of dissection, 
stenosis or vasospasm [12]. Patients were clas-
sified into two groups based on postintervention 
TIMI flow grade [11]. No reflow was defined as 
TIMI flow grades 0–2 (no-reflow group) and reflow 
was defined as TIMI 3 flow grade [12–15].
Patients with culprit lesion in left main coro-
nary artery, left main stenosis > 50%, previ-
ous coronary artery bypass surgery, cardiogenic 
shock, pain to balloon time > 12 h, treatment 
with fibrinolytics in previous 24 h, active infec-
tious or inflammatory diseases, presence of any 
chronic inflammatory-autoimmune disease includ-
ing rheumatologic disorders, hematalogic diseases, 
end-stage liver and renal failures, and known malig-
nancy were excluded from the current study. Study 
protocol was approved by the local institutional 
Ethics Committee.
Coronary intervention
All participants underwent coronary angiogra-
phy performed in multiple orthogonal projections 
using Judkins technique. To achieve maximal 
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dilatation each coronary angiogram was preceded 
by intracoronary injection of 100 µg nitroglyc-
erin. All primary PCI procedures were done using 
standard femoral route with 6-Fr or 7-Fr guiding 
catheters. The choice of balloon predilatation, pri-
mary stenting and stent type (BMS or DES) was 
at discretion of treating operator. Coronary blood 
flow was analyzed according to TIMI flow grade. 
TIMI flow grades were analyzed by two different 
interventional cardiologists blinded to patients’ 
clinical data. Intra and interobserver variabilities 
were obtained from random sample of 100 patients. 
Intra and interobserver variability for TIMI 0 and 
1 flow grades were 4% and 6%, respectively. While 
intra and interobserver variability for TIMI 2 flow 
grade were 2% and 2.4%, respectively; both in-
traobserver and interobserver variability for TIMI 
3 flow grade was 0%.
Multivessel disease was defined as presence 
of at least 1 lesion with greater than 50% diameter 
stenosis in ≥ 1 major epicardial coronary artery 
or its major branches remote from infarct related 
artery (IRA).
To evaluate clot burden we performed TIMI 
thrombus scale in all patients [16]. In TIMI throm-
bus grade 0, no cine-angiographic characteristics of 
thrombus are present; in TIMI thrombus grade 1, 
possible thrombus is present with such angiogra-
phic characteristics as decreased contrast density, 
haziness, irregular lesion contour, or a smooth 
convex “meniscus” at the site of total occlusion 
suggestive but not diagnostic of thrombus; in TIMI 
thrombus grade 2, there is definite thrombus, with 
the largest dimensions £ 1/2 the vessel diameter; 
in TIMI thrombus grade 3, there is definite throm-
bus but with the largest linear dimension > 1/2 but 
< 2 vessel diameters; in TIMI thrombus grade 4, 
there is definite thrombus, with the largest dimen-
sion ≥ 2 vessel diameters; and in TIMI thrombus 
grade 5, there is total occlusion. Upon admission all 
the patients received aspirin 300 mg a day, bolus in-
travenous unfractioned heparin 5,000 IU (70 U/kg), 
clopidogrel with a loading dose of 300 mg and 
maintenance dose of 75 mg and nitroglycerine. 
Primary stenting was performed whenever pos-
sible although balloon predilatation was used in 
the remaining cases. The technical aspects of the 
procedure, duration and pressure of inflation were 
determined by individual operators. Primary PCI 
was performed as quickly as possible (average 
door to first balloon time 78 ± 14 min). The use of 
other medications, including intravenous tirofiban 
(12 h) was left at the discretion of the attending 
operator (including bolus tirofiban administration). 
In patients undergoing tirofiban infusion the agent 
was administered after primary PCI in the coronary 
care unit.
Blood analysis and echocardiography
Venous blood samples were drawn from an-
tecubital veins immediately after obtaining ECG. 
Whole blood counting parameters were analyzed 
by a Sysmex K-1000 and Sysmex XN-10 Auto-
mated Hematology Analyzer (Sysmex Corporation, 
Kobe, Japan) autoanalyzer within 5 min of blood 
sampling. Whole blood sample collected in tripo-
tassium ethylenediamineteteraacetic acid (EDTA) 
(7.2 mg) tubes. In all study participants transtho-
racic echocardiography was performed before 
primary PCI in the coronary care unit. Estimated 
glomerular filtration rate (eGFR) was calculated 
using with the Chronic Kidney Disease Epide-
miology Collaboration (CKD-EPI). All echocar-
diographic measurements were made using com-
mercially available devices (Vivid 3® and Vivid 7®, 
GE Medical System, Horten, Norway) with 
a 3.5-MHz transducer. To evaluate left ventricular 
ejection fraction (LVEF) the Simpson’s method 
was used [17].
Major adverse cardiovascular events
Major adverse cardiovascular events were 
defined as in-stent thrombosis, nonfatal MI, and in-
hospital mortality during the in-hospital follow-up 
period. In-stent thrombosis was defined as angio-
graphically documented total occlusion. Non-fatal 
MI was defined as recurrent chest pain and/or 
development of new ECG changes accompanied 
by a new increase ≥ 20% of cardiac biomarkers 
measured after the recurrent event. In-hospital 
mortality had to be verified as death from MI, 
cardiac arrest, or other cardiac causes.
Statistical analysis
Continuous variables were tested for normal 
distribution by Kolmogorov-Smirnov test. Con-
tinuous data were expressed as mean ± standard 
deviation or median (interquartile range) if not nor-
mally distributed and compared using independent 
samples t-test or Mann-Whitney-U tests between 
study groups. Categorical variables were expressed 
as percentages and analyzed with c2 test. Differ-
ences between groups were considered significant 
at p < 0.05 two sided.
We investigated the effects of different vari-
ables on no reflow by calculating odds ratios (ORs) 
in univariate analysis for all the variables. Variables 
for which the unadjusted p value < 0.10 in logistic 
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regression analysis were identified as potential risk 
markers and included in the full model. We reduced 
the model by using backward elimination and we 
eliminated potential risk markers by using likeli-
hood ratio tests. A p value < 0.05 was considered 
statistically significant two sided. Statistical analy-
ses were performed by using SPSS 15.0 Statistical 
Package Program for Windows (SPSS Inc., Chicago, 
Illinois, USA).
Results
This study included 580 STEMI patients (77% 
men, mean age: 59 ± 12 years). The patients were 
divided into two groups according to TIMI flow 
grades after primary PCI. The patients with TIMI 
flow grades 0–2 formed no-reflow group (n = 198, 
144 men, mean age: 62 ± 11 years) and reflow 
group 2 (n = 398, 307 men, mean age: 58 ± 12 
years), respectively. Baseline clinical, demographi-
cal and laboratory parameters were listed in Table 1. 
Regarding demographical parameters, patients 
with no-reflow were older than those with reflow 
(62 ± 11 vs. 58 ± 12 years, p = 0.001). Also, more 
men were in the reflow group (80.4% vs. 72.7%, 
p = 0.0369). With respect to risk factors, there 
were statistically significant differences in pres-
ence of diabetes mellitus (p = 0.001) and previous 
CAD (p < 0.001) as shown in Table 1. Besides, 
eGFR values were lower in patients with no-reflow 
compared to those in reflow patients (69 vs. 77, 
p = 0.001).
The comparison of angiographic and echocardi-
ographic characteristics of the two groups showed 
Table 1. Baseline demographical, clinical and laboratory characteristics of the study patients.
No-reflow (n = 198) Reflow (n = 382) P
Age [years] 62 ± 11 58 ± 12 0.001
Sex (male) 144 (72.7%) 307 (80.4%) 0.036
Body mass index [kg/m2] 26.55 ± 2.15 26.35 ± 2.25 0.305
Previous CAD 65 (32.8%) 70 (18.3%) < 0.001
Diabetes 72 (36.4%) 89 (23.3%) 0.001
Hypertension 92 (46.5%) 155 (40.6%) 0.185
Smoking 108 (54.5%) 218 (57.1%) 0.561
Family history 37 (18.7%) 85 (22.2%) 0.318
Preprocedural medications:
Aspirin 122 (61.6%) 248 (64.9%) 0.432
Diuretic 25 (12.6%) 39 (10.2%) 0.378
BAB 120 (60.6%) 250 (65.4%) 0.250
ACE-I 133 (67.2%) 277 (72.5%) 0.180
Statin 127 (64.1%) 257 (67.3%) 0.449
Peak CK-MB [U/L] 102 (28–144) 90 (24–149) 0.428
Total cholesterol [mg/dL] 177 (146–210) 183 (156–216) 0.112
TG [mg/dL] 117 (80–158) 120 (78–172) 0.643
LDL [mg/dL] 115 (90–140) 116 (91–140) 0.785
HDL [mg/dL] 37 (31–44) 39 (34–45) 0.584
TC/HDL ratio 4.64 (3.97–5.60) 4.81 (4.00–5.68) 0.407
TG/HDL ratio 3.08 (1.97–4.84) 3.08 (1.87–5.00) 0.933
Serum glucose [mg/dL] 149 (118–210) 142 (114–119) 0.157
Serum urea [mg/dL] 40 (30–52) 37 (29–53) 0.584
Creatinine [mg/dL] 1.06 (0.90–1.30) 1.01 (0.90–1.18) 0.158
eGFR [mL/min/1.73 m2] 69 (51–86) 77 (63–91) 0.001
Uric acid [mg/dL] 6.1 (5.4–7.1) 5.9 (5.0–7.6) 0.188
Data are presented as mean ± standard deviation, median (interquartile range) or n (%); CAD — coronary artery disease; BAB — beta-adren-
ergic blocker; ACE-I — angiotensin converting enzyme inhibitor; CK-MB — creatine kinase-MB isoenzyme; TC — total cholesterol; TG — tri-
glyceride; LDL — low density lipoprotein; HDL — high density lipoprotein; eGFR — estimated glomerular filtration rate
www.cardiologyjournal.org 87
Turgay Celık et al., RDW-platelet ratio STEMI
no statistically significant differences apart from 
chest pain to balloon time,  admission LVEF values, 
TIMI thrombus grade, tirofiban use, and presence 
of multivessel disease (Table 2). Pain to balloon 
time in no-reflow group was longer than that of the 
patients in reflow group as presented in Table 2 
(6.0 vs. 5.5 h, p < 0.001). Also no-reflow group had 
higher TIMI thrombus grades and tirofiban use 
(Table 2; p < 0.006 and p = 0.002, respectively). 
There was more patients with multivessel disease 
in no-reflow group compared to that of reflow 
group (Table 2; 70.2% vs. 46.3%, p = 0.001). The 
left anterior descending coronary artery was the 
most common IRA in both study groups. Percent 
stent implantations and type of stents were similar 
among groups. Admission LVEF was lower in the 
no-reflow group compared to those of reflow group 
as shown in Table 2 (46.0 ± 9.5% vs. 48.6 ± 8.2%, 
p < 0.001).
The comparison of admission hematological pa-
rameters of both groups were presented in Table 3. 
According to admission whole blood cell (WBC) 
count results, the patients in no-reflow group had 
significantly higher WBC count, neutrophil and 
lymphocyte percentages, RDW, platecrit, NLR and 
RPR (Fig. 1) when compared to those in reflow 
patients (Table 3).
Effects of some clinically important variables 
on the no-reflow were analyzed by using univari-
ate and multivariate logistic regression analyses. 
Data for two groups were combined and all the 
variables were analyzed in univariate analysis as 
Table 2. Angiographic and echocardiographic characteristics of the study patients.
No-reflow (n = 198) Reflow (n = 382) P
Pain to balloon time [h] 6.0 (5.0–6.5) 5.5 (4.0–6.0) < 0.001
Tirofiban use 67 (33.8%) 83 (21.7%) 0.002
Admission LVEF [%] 46.0 ± 9.5 48.6 ± 8.2 0.001
TIMI thrombus grade: 0.006
Grade 0 5 (25%) 26 (6.8%)
Grade 1 10 (5.1%) 20 (5.2%)
Grade 2 21 (10.6%) 38 (9.9%)
Grade 3 29 (14.6%) 90 (23.6%)
Grade 4 46 (23.2%) 54 (14.1%)
Grade 5 87 (43.9%) 154 (40.3%)
Number of narrowed vessel: 0.001
Single vessel 59 (29.8%) 205 (53.7%)
Multivessel 139 (70.2%) 177 (46.3%)
Infarct related artery: 0.823
LAD 91 (46.0%) 179 (46.9%)
CFX 38 (19.2%) 79 (20.7%)
RCA 69 (34.8%) 124 (32.5%)
PCI procedure:
Balloon angioplasty 15 (7.6%) 20 (5.2%) 0.745
Balloon + stenting 147 (74.2%) 272 (71.3%) 0.320
Primary stenting 36 (18.2%) 90 (23.5%) 0.295
Stent type: 0.125
BMS 169 (85.4%) 315 (82.5%)
DES 14 (7.1%) 47 (12.3%)
Final balloon pressure [atm] 16.15 ± 2.46 16.43 ± 2.59 0.224
Stent length [mm] 18.08 ± 4.69 17.86 ± 3.89 0.147
Stent diameter [mm] 3.20 ± 0.39 3.14 ± 0.40 0.620
Data are presented as mean ± standard deviation, median (interquartile range) or n (%); LVEF — left ventricular ejection fraction; TIMI — 
thrombolysis in myocardial infarction; LAD — left anterior descending artery; CFX — circumflex coronary artery; RCA — right coronary artery; 
PCI — percutaneous coronary intervention; BMS — bare metal stent; DES — drug eluting stent
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the predictor of no-reflow as shown in Table 4. 
Some variables associated with impaired flow after 
primary PCI were significantly different between 
two study groups. Independent contributions age, 
male gender, diabetes mellitus, LVEF on admis-
sion, eGFR, pain to balloon time, multivessel 
disease, TIMI thrombus grade, tirofiban, aspirin, 
previous CAD, NLR, platecrit and RPR were ana-
lyzed in multivariate backward logistic regression 
(Table 4). On multivariate analysis, pain to balloon 
time, multivessel disease, TIMI thrombus grade, 
tirofiban, aspirin, previous CAD, NLR, platecrit and 
RPR remained independent predictors of no reflow 
after primary PCI. Adjusted ORs were calculated as 
1.52 for pain to balloon time (p < 0.001; CI = 1.19–
–1.81), 2.63 for multivessel disease (p < 0.001; 
CI = 1.29–1.81), 1.59 for TIMI thrombus grade 
(p < 0.001; CI = 1.32–1.92), 0.30 for tirofiban 
(p < 0.001; CI = 0.19–0.49), 0.41 for aspirin (p = 0.003; 
CI = 0.22–0.73),  2.54 for previous CAD 
(p = 0.001; CI = 1.49–4.33), 1.07 for NLR (p = 0.042; 
CI = 1.01–1.14), 1.23 for platecrit (p < 0.001; 
CI = 1.16–1.30) and 1.87 for RPR (p < 0.001; 
CI = 1.54–2.26) as shown in Table 4.
In-hospital MACEs of the study patients 
were given in Table 5. Patients in no-reflow group 
tended to be higher percent in-hospital MACE, 
including nonfatal MI and cardiovascular mortality 
compared to those of reflow patients (p < 0.001 for 
all parameters).
Discussion
The present study demonstrated that WBC 
count, neutrophil and lymphocyte percentages, RDW, 
platecrit, NLR and RPR values were higher among 
patients with no-reflow.
Due to the growing understanding in re-
cent years of the role of inflammatory status in 
the initiation and progression of atherosclerosis, 
epidemiological studies have focused on mark-
ers of the inflammatory status and its relation to 
adverse outcomes in patients with different CAD 
phenotypes. In patients with STEMI undergoing 
coronary angiography, short-term mortality risk 
Table 3. Comparison of hematological parameters of the study groups.
No-reflow (n = 198) Reflow (n = 382) P
White blood cell [×109/L] 11.7 (9–15) 11.0 (9–13) 0.088
Neutrophil [%] 64.15 (47–81) 59.14 (43–72) 0.001
Lymphocyte [%] 16.85 (11–24) 18.69 (12–26) 0.017
Eosinophil [%] 1.36 (1–1.9) 1.54 (1–2.4) 0.158
Basophil [%] 0.60 (0.3–0.9) 0.64 (0.3–0.7) 0.705
Monocyte [%] 6.45 (5.0–8.1) 7.16 (5.6–8.9) 0.146
Neutrophil–lymphocyte ratio 4.11 (3–5.3) 2.80 (2–4.37) < 0.001
Hemoglobin [g/dL] 14.00 ± 1.78 14.30 ± 1.98 0.100
RDW [%] 13.83 ± 1.44 13.39 ± 1.42 < 0.001
Platelet count [×109/L] 238 (190–289) 246 (200–287) 0.285
Platecrit 0.23 (0.19–0.30) 0.21 (0.18–0.25) 0.003
Platelet–lymphocyte ratio 130 (91–180) 118 (82–179) 0.280
RDW-platelet ratio 5.68 (4.79–7.39) 5.38 (4.55–6.67) 0.016
Data are presented as mean ± standard deviation or median (interquartile range); RDW — red cell distribution width
Figure 1. Median red cell distribution width to platelet 
ratios were statistically significantly higher in patients 
with no-reflow compared to those of the patients with 
reflow.
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Table 4. Effects of various variables on no reflow in univariate and multivariate logistic regression 
analyses.
Unadjusted OR 95% CI P Adjusted OR* 95% CI P
Age 1.03 1.01–1.04 < 0.001 1.01 0.99–1.03 0.300
Gender (male) 1.54 1.03–2.29 0.037 1.16 0.69–1.95 0.572
Beta-blocker 0.81 0.57–1.15 0.251
Hypertension 1.27 0.89–1.79 0.174
Diabetes 1.88 1.29–2.74 0.001 1.34 0.81–2.22 0.251
LVEF 0.97 0.95–0.99 0.001 0.99 0.96–1.01 0.365
Smoking 0.90 0.63–1.27 0.562
Body mass index 1.04 0.96–1.12 0.304
eGFR 0.99 0.99–1.00 0.295 1.00 0.99–1.01 0.221
Stent length 1.00 0.97–1.04 0.619
Stent diameter 0.95 0.89–2.16 0.148
Pain to balloon time 1.52 1.32–1.74 < 0.001 1.52 1.29–1.81 < 0.001
Multivessel disease 2.73 1.89–3.93 < 0.001 2.63 1.68–4.11 < 0.001
TIMI thrombus grade 1.15 1.02–1.29 0.027 1.59 1.32–1.92 < 0.001
Tirofiban 0.54 0.37–0.80 0.002 0.30 0.19–0.49 < 0.001
Aspirin 0.87 0.61–1.24 0.430 0.41 0.22–0.73 0.003
Previous CAD 2.18 1.47–3.23 < 0.001 2.54 1.49–4.33 0.001
NLR 1.11 1.04–1.17 0.001 1.07 1.01–1.14 0.042
Platecrit 1.04 1.02–1.07 0.002 1.23 1.16–1.30 < 0.001
RDW-platelet ratio 1.12 1.02–1.23 0.022 1.87 1.54–2.26 < 0.001
*Adjusted for age, gender, diabetes, LVEF on admission, eGFR, pain to balloon time, multivessel disease, TIMI thrombus grade, tirofiban,  
aspirin, previous CAD, NLR, platecrit and RDW-platelet ratio; OR — odd ratio; CI — confidence interval; LVEF — left ventricular ejection  
fraction; eGFR — estimated glomerular filtration rate; TIMI — thrombolysis in myocardial infarction; CAD — coronary artery disaese;  
NLR — neutrophil–lymphocyte ratio; RDW — red cell distribution width
Table 5. In-hospital major adverse cardiac events of study groups.
No-reflow (n = 198) Reflow (n = 382) P
In-hospital MACEs: 55 (27.8%) 31 (8.1%) < 0.001
In-stent thrombosis 10 (5.1%) 13 (3.4%) 0.335
Non-fatal myocardial infarction 30 (15.2%) 13 (3.4%) < 0.001
In-hospital mortality 46 (23.2%) 12 (3.1%) < 0.001
Data are presented as mean ± standard deviation, median (interquartile range) or n (%); MACE — major adverse cardiac events
displays a considerable variability. Early and indi-
vidualized risk stratification in each patient allows 
for a more precise decision-making with regard 
to the choice of pharmacologic and interventional 
treatments, allocation of clinical resources and tri-
age among alternative levels of hospital care. To 
make such kind of planning, one must be aware of 
the risk factors related to morbidity and mortality 
in STEMI patients undergoing angiography. One 
of the early late mortality factors as the no-reflow 
phenomenon may be defined as incomplete reper-
fusion at the microvascular level despite adequate 
recanalization of the occluded artery. The existence 
of no-reflow phenomenon was initially debated; 
however, this pathological process can be acceler-
ated by coronary reperfusion, which gives rise 
to tissue edema, endothelial injury, plugging of 
capillaries by neutrophils and microthrombi, and 
inflammation due to generation of free radicals and 
complement activation [18]. Several studies have 
shown a relationship between no-reflow phenom-
enon and increased inflammatory activity. Recent 
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studies have shown that no-reflow phenomenon is 
associated with a higher prevalence of early and 
late morbidity and mortality [3, 19, 20]. The CBC 
is one of the most frequently ordered laboratory 
tests in clinical practice. CBC is the most widely 
available laboratory data in early in-hospital period, 
universally available in the first 30 min. CBC is an 
easy, inexpensive, routine examination technique 
that give us information about the blood contents; 
the red and white cells, platelets, the counts and 
dimensions of subgroups of cells, and parameters 
like the distribution widths, some ratios. Various 
studies have evaluated the performance of these 
hematological CBC parameters to predict disease 
severity and mortality risk of STEMI. For ex-
ample, platelets play a central role in the patho-
physiology of an acute MI by contributing to the 
thrombotic occlusion of the IRA [21]. In addition 
to platelet count, platecrit is also inexpensive and 
easily available marker, which provides complete 
information on total platelet mass. High platecrit 
values on admission are independently associated 
with long-term adverse outcomes in patients with 
STEMI who undergo primary angioplasty [7]. 
Also, NLR has received attention due to its role as 
an independent prognostic factor for CAD. Many 
studies have investigated the relation between 
NLR and the short-term morbidity and mortality 
in patient with STEMI undergoing primary PCI. 
The NLR, an inexpensive and easily measurable 
laboratory variable, is independently associated 
with the development of no-reflow and in-hospital 
MACEs in patients with STEMI undergoing pri-
mary PCI [22]. We have reported same results in 
present study. An elevated RDW has been reported 
to be associated with mortality and other severe 
adverse outcomes in patients with STEMI who 
undergo primary angioplasty [23]. RDW is a widely 
available, easily derived and reproducible marker 
of inflammation. Increased RDW, independent of 
hemoglobin values, have been demonstrated to 
be associated with negative clinical outcomes in 
patients with heart failure, previous MI, stable 
CAD, strokes, infections and peripheral artery 
disease [24]. The RDW was increased in patients 
and was positively correlated with bilirubin, cre-
atinine levels, prothrombin time, and negatively 
correlated with platelet count and albumin level. 
The half-life of red blood cells is higher than 
bilirubin and albumin; therefore, the RDW repre-
sented a more stable index. RPR, a novel marker 
is a more powerful predictive index of significant 
fibrosis but is equally powerful in the prediction 
of fibrosis [23]. The RPR reflects inflammation 
severity. RPR is used in clinical practice with the 
accompanying assessments, it could be a useful 
and important marker for predicting the mortality 
of patients with some chronic diseases [25]. RPR, 
a cheap, routinely available and easily calculated 
index, can predict inflammation in patients with 
no-reflow when considering the pathophysiology 
of no-reflow phenomenon in patients undergoing 
primary PCI. In context, we have considered that 
RPR levels may be associated with no-reflow 
phenomenon. RPR levels are higher in no-reflow 
phenomenon compared with reflow groups. Also, 
we reported that RPR levels are independent pre-
dictors of no-reflow after primary PCI. So, RPR 
is considered as a novel inflammatory marker in 
patients with STEMI.
Limitations of this study
The main limitation of our study is the rela-
tively small sample size. Because high-sensitivity 
C-reactive protein is not evaluated routinely in 
patients undergoing elective coronary angiography 
in our department, this test was not included to 
compare inflammatory status between the groups. 
Furthermore, we did not analyze the causes of 
elevated RDW values, such as iron, folic acid or 
vitamin B12 deficiency. Finally, we excluded some 
diseases that may influence RPR levels; however 
some diseases may be unrecognized in our study 
group.
Conclusions
Admission RPR levels are simple, easily ob-
tained inflammatory marker in no-reflow and 
in-hospital MACEs among STEMI patients under-
going primary PCI. Therefore, the predictive per-
formance of the RPR should be further confirmed 
in multi-center, prospectively designed studies.
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